First Disclosures in Molecular Cancer Therapeutics present drugs for the first time in published literature, accompanied by pertinent translational investigations. Submissions are assessed based on ...
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...
The FDA approved the PD1 inhibitor atezolizumab plus hyaluronidase (Tecentriq Hybreza; Genentech), which helps the drug move into tissues, as a subcutaneous injection for the same adult indications as ...
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Radiology and Interventional Radiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts. *Corresponding Author: Bryan D. Choi, Department of Neurosurgery, Massachusetts ...
According to data presented at the ESMO Congress 2024, being held from September 13–17 in Barcelona, Spain, for patients with advanced renal cell carcinoma, oncologists should avoid prescribing ...
A new study finds that clinical trials are more likely to stop early if there is no genetic evidence for the treatment. Insufficient patient enrollment is the main cause for early termination in ...
Copyright held by the owner/author(s).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback